doi: 10.1161/hc0102.101365
(Circulation. 2002;105:85.)
© 2002 American Heart Association, Inc.
Basic Science Reports |
Genetic Alterations That Inhibit In Vivo Pressure-Overload Hypertrophy Prevent Cardiac Dysfunction Despite Increased Wall Stress
From the Departments of Medicine (G.E., A.R., S.V.N.P., H.T., H.A.R.) and Surgery (W.J.K.), Duke University Medical Center, Durham, NC, and the Department of Pharmacology, University of Pennsylvania, Philadelphia (S.A.T.).
Correspondence to Howard A. Rockman, MD, Department of Medicine, Duke University Medical Center, DUMC 3104, Durham, NC, 27710. E-mail h.rockman{at}duke.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— A long-standing hypothesis has been that hypertrophy is compensatory and by normalizing wall stress acts to maintain normal cardiac function. Epidemiological data, however, have shown that cardiac hypertrophy is associated with increased mortality, thus casting doubt on the validity of this hypothesis.
Methods and Results— To determine whether cardiac hypertrophy is necessary to preserve cardiac function, we used 2 genetically altered mouse models that have an attenuated hypertrophic response to 8 weeks of pressure overload. End-systolic wall stress (
es) obtained by sonomicrometry after 1 week of pressure overload showed complete normalization of es in pressure-overloaded wild-type mice (287±39 versus sham, 254±34 g/cm2), whereas the blunted hypertrophic response in the transgenic mice was inadequate to normalize es (415±81 g/cm2, P<0.05). Remarkably, despite inadequate normalization of es, cardiac function as measured by serial echocardiography showed little deterioration in either of the pressure-overloaded genetic models with blunted hypertrophy. In contrast, wild-type mice with similar pressure overload showed a significant increase in chamber dimensions and progressive deterioration in cardiac function. Analysis of downstream signaling pathways in the late stages of pressure overload suggests that phosphoinositide 3-kinase may play a pivotal role in the transition from hypertrophy to heart failure.
Conclusions— These data suggest that under conditions of pressure overload, the development of cardiac hypertrophy and normalization of wall stress may not be necessary to preserve cardiac function, as previously hypothesized.
Key Words: contractility • hypertrophy • heart failure • receptors, adrenergic, beta • signal transduction
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Heart failure is a major health problem estimated to affect 700 000 individuals per year in the United States alone.1 An important cause of heart failure is chronic pressure overload, such as that which occurs with longstanding hypertension. At a cellular level, myocytes respond to pressure overload with the parallel addition of sarcomeres, resulting in an increase in myocyte width and ventricular wall thickness.2
See p 8
It has been a long-standing hypothesis that the development of myocardial hypertrophy is a compensatory mechanism in response to disease states that produce increased cardiac workload to normalize wall stress and maintain normal cardiac function, thereby preventing the development of heart failure.2,3 Although this remodeling may act to normalize wall stress, results from the Framingham Heart Study show an association between ventricular hypertrophy and increased cardiac mortality,4 casting doubt on the validity of the wall-stress hypothesis. Thus, whether cardiac hypertrophy in response to pressure overload is adaptive or maladaptive remains a fundamental issue in the pathogenesis of heart failure.
To address this issue, we studied the effect of long-term pressure overload on the development of heart failure using 2 murine models that have an attenuated hypertrophic response to pressure overload: (1) cardiac gene–targeted mice with the myocardial expression of a carboxyl terminal peptide of G
q (TgGqI) that specifically inhibits Gq-mediated signaling5 and (2) genetically altered mice that lack endogenous norepinephrine and epinephrine created by disruption of the dopamine ß-hydroxylase gene (Dbh-/-), the essential enzyme in the biosynthetic pathway converting dopamine to norepinephrine.6,7
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Experimental Animals
Genetically altered and strain-matched wild-type mice 3 to 4 months of age were used for this study.5–8 Animals were handled according to approved protocols and animal welfare regulations by the Institutional Review Board at Duke University Medical Center.
Transthoracic Echocardiography
2D guided M-mode echocardiography was performed in conscious mice with an HDI 5000 echocardiograph (ATL) as previously described.9
In Vivo Pressure Overload
Mice were anesthetized with a mixture of ketamine (100 mg/kg) and xylazine (2.5 mg/kg), and transverse aortic constriction (TAC) was performed as previously described.10 Eight weeks after surgery, the transstenotic gradient was assessed by recording the simultaneous measurement of right carotid and left axillary arterial pressures.
Pressure-Volume and Stress-Strain Analysis in 7-Day Pressure-Overloaded Mice
In separate experiments 7 days after TAC, pressure-volume and stress-strain analysis was performed as previously described with modifications.9 After the chest had been opened, afterload was normalized by removal of the 7-day suture, and a new suture ligature was placed around the transverse aorta to manipulate loading conditions. Five miniature piezoelectric crystals (4 endocardial and 1 epicardial) were implanted in the beating heart to obtain 2 orthogonal dimensions and instantaneous wall thickness throughout the cardiac cycle (Sonometrics). The end-systolic pressure, the end-systolic volume, the volume axis intercept, and the slope of the end-systolic pressure-volume relation (E'max) value reflecting cardiac contractility were obtained. Instantaneous stress () and strain (
) were calculated and stress-strain loops generated as described.11 Maximum systolic stiffness (EaVmax), an index of left ventricular (LV) contractility independent of ventricular size, was obtained from the following relation: es=EaVmaxxes, where es is end-systolic stress and es is end-systolic midwall natural strain.
Mitogen-Activated Protein Kinase Activity
Mitogen-activated protein kinase (MAPK) activities were assessed from LV extracts as the capacity of immunoprecipitated ERK2-p42/ERK1-p44, p38, p38ß, and JNK1-p46/JNK3 MAPK to phosphorylate in vitro substrates (myelin basic protein or GST-cJun) as described.12
G Protein–Coupled Receptor Kinase Activity by Rhodopsin Phosphorylation
Cytosolic extracts (300 µg of protein) were incubated with rhodopsin-enriched rod outer segments in 25 µL of lysis buffer with 10 mmol/L MgCl2 and 0.1 mmol/L ATP containing [
-32P]ATP.13 Reactions were incubated in white light for 15 minutes, quenched with 300 µL of ice-cold lysis buffer, centrifuged, and resolved by SDS-PAGE.13 Phosphorylated rhodopsin was visualized by autoradiography and quantified with a PhosphorImager.
Immunoblotting
Immunodetection of myocardial levels of ß-adrenergic receptor kinase 1 (ßARK1) was performed on cytosolic extracts with a polyclonal anti-ßARK1 antibody (Santa Cruz Biotechnology) as previously described.13 After transfer to polyvinylidine difluoride membrane (Biorad), the 80-kDa ßARK1 protein was visualized by chemiluminescence detection (ECL, Amersham).
ßAR Density and Adenylyl Cyclase Activity
Myocardial membranes were prepared by homogenization of whole hearts in ice-cold buffer as described.13 Total ßAR density was determined by incubation of 25 µg of membranes with a saturating concentration (80 pmol/L) of 125I-labeled cyanopindolol and 20 mmol/L alprenolol to define nonspecific binding.13,14 Assays were conducted at 37°C for 60 minutes and then filtered over GF/C glass fiber filters (Whatman), then washed and counted in a gamma counter. Adenylyl cyclase activity was measured as described15 on purified cardiac membranes.
Phosphoinositide 3-Kinase and v-Akt Activity
Phosphoinositide 3-kinase (PI3K) activity was performed on clarified myocardial extracts after immunoprecipitation with an antibody to PI3K as previously described.16,17 Phosphorylated active v-Akt from cardiac extracts prepared as above was detected by immunoblotting with rabbit polyclonal phospho-Akt (Ser473) and rabbit polyclonal Akt (Ser473) antibodies (Cell Signaling Technology).16
Statistical Analysis
Data are expressed as mean±SEM. Two-way repeated-measures ANOVA was used to evaluate the echo measurements, end-systolic pressure-volume relation, and stress-strain variables under basal conditions and with dobutamine stimulation. When appropriate, post hoc analysis was performed with a Scheffé test. For all analyses, a value of P<0.05 was considered significant. For the data from MAPK signaling, 2-sample comparisons were performed with Student’s t test, and multigroup comparisons were made with a 1-way ANOVA and Tukey’s test.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Wall Stress and Stress-Strain Relations in 7-Day Banded Mice
In vivo wall stress in banded wild-type and TgGqI mice was measured 7 days after TAC (Figure 1). End-systolic wall stress (
es) in pressure-overloaded hearts was calculated from the stress-strain loops after removal of the suture surrounding the transverse aorta. To estimate the in vivo end-systolic wall stress ('es) in the intact-banded mouse heart, the pressure gradient before removal of the suture was added to the LV systolic pressure measured after removal of the suture. Wall stress was completely normalized in banded wild-type mice because of the induction of adequate hypertrophy (Figure 1, A and B; Table 1). In contrast, wall stress was significantly elevated in banded TgGqI mice because the level of hypertrophy was inadequate (Figure 1, A and B, Table 1). Furthermore, basal and agonist-stimulated contractile function, measured by LV dP/dtmax and E'max, were similar in banded wild-type and TgGqI mice (Table 1).
|
P<0.02 vs sham; *P<0.02 basal TgGqI vs sham, and TgGqI at high afterload vs wild-type at high afterload.
|
Physiological Response to Long-Term In Vivo Pressure Overload in Wild-Type and TgGqI Mice
Serial echocardiography was performed in conscious wild-type and TgGqI mice before and 4 weeks and 8 weeks after TAC. Wild-type mice developed progressive LV enlargement and dysfunction, as shown by a 40% reduction in percent fractional shortening (%FS), a 100% increase in LV end-systolic dimension (LVESD), and a 27% increase in LV end-diastolic dimension (LVEDD) compared with the basal measurements (Figure 2, A through D, Table 2). In contrast, the TgGqI mice showed significantly less deterioration in cardiac function than the wild-type banded mice (Figure 2, A through D, Table 2).
|
P<0.05 TgGqI at 8 weeks vs before TAC. D, Representative serial M-mode echocardiographic tracings before and 4 weeks and 8 weeks after TAC. E, LVW/BW in banded wild-type and TgGqI mice 8 weeks after TAC. *P<0.01 TAC vs sham either wild-type or TgGqI;
|
At 8 weeks after TAC, the increase in the ratio of LV weight to body weight (LVW/BW) in banded TgGqI mice was significantly blunted compared with the banded wild-type mice, despite a similar transstenotic pressure gradient (Figure 2E, Table 2). Postsurgical mortality in banded TgGqI mice was not different from that in wild-type mice at 16% and 18%, respectively. In addition, peak LV systolic pressure, as measured by the carotid arterial pressure proximal to the stenosis, was not different after TAC in the TgGqI mice from that in control mice (190.2±6.2 versus 183.1±8.3 mm Hg), confirming matched hemodynamic loads.
Physiological Response to Long-Term In Vivo Pressure Overload in Dbh-/- and Control Mice
TAC in control mice resulted in a significant reduction in %FS and an increase in LVESD and LVEDD compared with baseline measurements (Figure 3, A through D, Table 3). In marked contrast, LVESD, LVEDD, and %FS in Dbh-/- mice remained essentially normal 4 and 8 weeks after TAC compared with the pre-TAC measurements (Figure 3, A through D, Table 3). Remarkably, even though cardiac hypertrophy in Dbh-/- mice was significantly inhibited (Figure 3, E and F, Table 3), there was no deterioration of cardiac function. Postsurgical mortality in banded Dbh-/- mice was not different from that in wild-type mice at 17% and 21%, respectively. In addition, peak LV systolic pressure was not different after TAC in the Dbh-/- mice compared with control mice (178.5±6.4 versus 174.1±5.5 mm Hg). These data show that the blunting of the hypertrophic response and the resultant increase in wall stress are associated with less deterioration in cardiac function despite the continued presence of a pressure load on the heart.
|
|
ßAR Signaling in Banded TgGqI and Dbh-/- Mice
ßAR levels, adenylyl cyclase activity, and ßARK1 activity were measured in hearts from TgGqI and Dbh-/- mice after 8 weeks of pressure overload. ßAR downregulation occurred after TAC in both wild-type and TgGqI mice but was prevented in the Dbh-/- mice (Figure 4, A and D). Furthermore, the impaired adenylyl cyclase activity observed in the wild-type banded mice (Figure 4, B and E) was not observed in either the banded TgGqI or Dbh-/- mice (Figure 4, B and E). NaF-stimulated adenylyl cyclase activity was impaired only in wild-type banded hearts, indicating a significant defect in postreceptor signaling (data not shown). Finally, a significant increase in G protein–coupled receptor kinase activity was detected in both wild-type and TgGqI banded hearts but was unchanged in the banded Dbh-/- mice (Figure 4, C and F). Taken together, these data suggest that the greater the attenuation of the hypertrophic response with chronic pressure overload, the less development of heart failure and the fewer abnormalities in ßAR signaling.
|
MAPK Signaling in Heart Failure
Because recent studies have shown that internalization of ßARs can lead to activation of MAPK signaling pathways,18,19 we evaluated ERK1/2, JNK, p38, and p38ß activity in heart extracts 8 weeks after TAC. All 3 MAPK pathways were activated in wild-type TAC hearts at 8 weeks (Figure 5, A and B). Importantly, ERK activation was significantly attenuated in hearts from banded TgGqI and Dbh-/- mice (Figure 5, A and B).
|
PI3K and v-Akt in Long-Term Pressure Overload
We recently showed that short-term pressure overload activates PI3K signaling,16 and this may contribute to internalization of ßARs.17 To determine whether PI3K signaling was altered after chronic pressure overload, we measured PI3K activity in sham and TAC hearts. Whereas PI3K and v-Akt were significantly activated in wild-type banded hearts (Figure 5, C and D), no increase in the PI3K pathway was observed in either the banded TgGqI mice or Dbh-/- mice (Figure 5, C and D).
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In this study, we demonstrate that in the mouse, the development of pressure-overload cardiac hypertrophy and normalization of wall stress does not prevent LV decompensation, as was previously hypothesized,2,3 but in fact is associated with progressive deterioration in cardiac function and LV chamber enlargement. Strikingly, in 2 different models, limiting the development of hypertrophy in response to chronic pressure overload is associated with little or no deterioration in cardiac function. By sonomicrometry, we show that normalization of wall stress did indeed occur in hypertrophied wild-type mice, whereas wall stress was increased by 2-fold in the TgGqI mice because of the lack of adequate hypertrophy. Thus, even though wall stress was not normalized in the TgGqI mice, these animals had significantly less LV deterioration with chronic pressure overload, demonstrating that elevated wall stress per se is not a trigger for ventricular decompensation.
PI3Ks are a conserved family of lipid kinases that play a pivotal role in cell proliferation, differentiation, cytoskeletal organization, membrane trafficking, and apoptosis.20 The finding of total ablation of PI3K activation in pressure-overloaded TgGqI and Dbh-/- mice compared with their banded wild-type controls may provide insight into the mechanisms involved. First, lack of PI3K activation can be observed with short-term (7-day) banding in TgGqI mice,16 a time point before the deterioration in LV function in wild-type banded mice. Second, ERK activation can occur via a PI3K-dependent pathway,21 which may account, in part, for the inhibition of ERK activation seen in both TgGqI and Dbh-/- mice after long-term TAC. Finally, human heart failure is associated with downregulation and desensitization of ßARs,22 and recent studies have shown a pivotal role for PI3K in the process of ßAR sequestration.17 In this study, pressure-overloaded Dbh-/- and TgGqI mice have little or mild alteration in cardiac ßAR signaling at 8 weeks, a time when banded control mice have impaired ßAR signaling. Taken together, the absence of PI3K activation in the TgGqI and Dbh-/- hearts after TAC suggests an important role for PI3K signaling in preventing heart failure progression after pressure overload that may be mediated through its effects on ßAR signaling.
Perhaps the signaling cascade most involved in the myocardial hypertrophic response is the MAPKs, including the ERK, JNK, and p38 kinases.23 All MAPKs were significantly activated 8 weeks after TAC in wild-type control mice, similar to what has been reported in human heart failure.24 In contrast, ERK was not activated in the TgGqI and Dbh-/- animals after TAC and may be a potential mechanism for the lack of deterioration in cardiac function. It has been postulated that in the hypertrophied heart, a chronic reduction in the ability to oxidize fats, resulting primarily from an ERK-mediated reduction in peroxisome proliferator–activated receptor- activity, may be maladaptive.25 Furthermore, recent evidence has linked agonist-induced internalization of ßARs to activation of the ERK pathway.18,19 Taken together, we postulate that if the activation of PI3K is blocked during the development of cardiac hypertrophy, the efficiency of ßAR internalization is diminished, leading to less ERK activation and a more favorable metabolic state in which fatty acids are used instead of glucose as the primary energy source.
Our study is consistent with recent reports showing no difference in cardiac function between hypertrophic and nonhypertrophic pressure-overloaded hearts in mice by either treatment with cyclosporine26 or deletion of the fibroblast growth factor-2 gene.27 Both studies were limited, however, because neither of the control study groups developed cardiac dysfunction over the time period examined.26,27
In conclusion, our study suggests that the development of cardiac hypertrophy and normalization of wall stress are not necessary to preserve cardiac function and that inhibition of PI3K may play an important role in the transition from hypertrophy to failure. These findings may have several important clinical implications in developing new therapeutic strategies to prevent the transition from cardiac hypertrophy to heart failure.
|
Acknowledgments |
|---|
This work was supported in part by National Institutes of Health grants HL-61558, HL-56687 (Dr Rockman), and HL-61690 (Dr Koch). Dr Rockman is a recipient of a Burroughs Wellcome Fund Clinical Scientist Award in Translational Research. We gratefully acknowledge Dr Lan Mao for her expertise in murine microsurgery and the generous gift of DOPS from Sumitomo Pharmaceuticals, Osaka, Japan.
|
Footnotes |
|---|
The first 2 authors contributed equally to this work.
Drs Esposito and Rapacciuolo are currently at Frederico II University, Naples, Italy.
Received August 3, 2001; revision received October 16, 2001; accepted October 17, 2001.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Abraham WT, Bristow MR. Specialized centers for heart failure management. Circulation. 1997; 96: 2755–2757.
2. Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest. 1975; 56: 56–64.
3. Chien KR. Genomic circuits and the integrative biology of cardiac diseases. Nature. 2000; 407: 227–232.[CrossRef][Medline] [Order article via Infotrieve]
4. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990; 322: 1561–1566.[Abstract]
5.
Akhter SA, Luttrell LM, Rockman HA, et al. Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science. 1998; 280: 574–577.
6. Thomas SA, Matsumoto AM, Palmiter RD. Noradrenaline is essential for mouse fetal development. Nature. 1995; 374: 643–646.[CrossRef][Medline] [Order article via Infotrieve]
7.
Cho MC, Rao M, Koch WJ, et al. Enhanced contractility and decreased ß-adrenergic receptor kinase-1 in mice lacking endogenous norepinephrine and epinephrine. Circulation. 1999; 99: 2702–2707.
8.
Rapacciuolo A, Esposito G, Caron K, et al. Important role of endogenous norepinephrine and epinephrine in the development of in vivo pressure-overload cardiac hypertrophy. J Am Coll Cardiol. 2001; 38: 876–882.
9. Esposito G, Santana LF, Dilly K, et al. Cellular and functional defects in a mouse model of heart failure. Am J Physiol. 2000; 279: H3101–H3112.
10.
Rockman HA, Ross RS, Harris AN, et al. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc Natl Acad Sci U S A. 1991; 88: 8277–8281.
11.
Mirsky I, Tajimi T, Peterson KL. The development of the entire end-systolic pressure-volume and ejection fraction-afterload relations: a new concept of systolic myocardial stiffness. Circulation. 1987; 76: 343–356.
12.
Esposito G, Prasad SV, Rapacciuolo A, et al. Cardiac overexpression of a Gq inhibitor blocks induction of extracellular signal–regulated kinase and c-Jun NH2-terminal kinase activity in in vivo pressure overload. Circulation. 2001; 103: 1453–1458.
13.
Choi DJ, Koch WJ, Hunter JJ, et al. Mechanism of beta-adrenergic receptor desensitization in cardiac hypertrophy is increased beta-adrenergic receptor kinase. J Biol Chem. 1997; 272: 17223–17229.
14.
Rockman HA, Chien KR, Choi DJ, et al. Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci U S A. 1998; 95: 7000–7005.
15.
Harding V, Jones L, Lefkowitz R, et al. Cardiac ßARK inhibition improves survival and augments ß blocker therapy in a mouse model of severe heart failure. Proc Natl Acad Sci U S A. 2001; 98: 5809–5814.
16.
Naga Prasad SV, Esposito G, Mao L, et al. Gß-dependent phosphoinositide 3-kinase activation in hearts with in vivo pressure overload hypertrophy. J Biol Chem. 2000; 275: 4693–4698.
17.
Naga Prasad SV, Barak LS, Rapacciuolo A, et al. Agonist-dependent recruitment of phosphoinositide 3-kinase to the membrane by ß-adrenergic receptor kinase 1: a role in receptor sequestration. J Biol Chem. 2001; 276: 18953–18959.
18.
Daaka Y, Luttrell LM, Ahn S, et al. Essential role for G protein-coupled receptor endocytosis in the activation of mitogen-activated protein kinase. J Biol Chem. 1998; 273: 685–688.
19.
Luttrell LM, Ferguson SS, Daaka Y, et al. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science. 1999; 283: 655–661.
20.
Rameh LE, Cantley LC. The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem. 1999; 274: 8347–8350.
21.
Lopez-Ilasaca M, Crespo P, Pellici PG, et al. Linkage of G protein-coupled receptors to the MAPK signaling pathway through PI 3-kinase gamma. Science. 1997; 275: 394–397.
22. Bristow MR. Why does the myocardium fail? Insights from basic science. Lancet. 1998; 352 (suppl 1): SI8–SI14.
23.
Sugden PH. Signaling in myocardial hypertrophy: life after calcineurin? Circ Res. 1999; 84: 633–646.
24.
Haq S, Choukroun G, Lim H, et al. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation. 2001; 103: 670–677.
25. Barger PM, Brandt JM, Leone TC, et al. Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. J Clin Invest. 2000; 105: 1723–1730.[Medline] [Order article via Infotrieve]
26.
Hill JA, Karimi M, Kutschke W, et al. Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. Circulation. 2000; 101: 2863–2869.
27. Schultz JE, Witt SA, Nieman ML, et al. Fibroblast growth factor-2 mediates pressure-induced hypertrophic response. J Clin Invest. 1999; 104: 709–719.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  B. Yoo, A. Lemaire, S. Mangmool, M. J. Wolf, A. Curcio, L. Mao, and H. A. Rockman {beta}1-Adrenergic receptors stimulate cardiac contractility and CaMKII activation in vivo and enhance cardiac dysfunction following myocardial infarction Am J Physiol Heart Circ Physiol, October 1, 2009; 297(4): H1377 - H1386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Oceandy, A. Pickard, S. Prehar, M. Zi, T. M.A. Mohamed, P. J. Stanley, F. Baudoin-Stanley, R. Nadif, S. Tommasi, G. P. Pfeifer, et al. Tumor Suppressor Ras-Association Domain Family 1 Isoform A Is a Novel Regulator of Cardiac Hypertrophy Circulation, August 18, 2009; 120(7): 607 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Hedhli and C. Depre Proteasome inhibitors and cardiac cell growth Cardiovasc Res, August 7, 2009; (2009) cvp226v2. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R J Hassink, H Nakajima, H O Nakajima, P A Doevendans, and L J Field Expression of a transgene encoding mutant p193/CUL7 preserves cardiac function and limits infarct expansion after myocardial infarction Heart, July 15, 2009; 95(14): 1159 - 1164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-H. Choi, D. B. Cowan, A. M. Moran, S. D. Colan, C. Stamm, K. Takeuchi, I. Friehs, P. J. del Nido, and F. X. McGowan Jr. Myocyte apoptosis occurs early during the development of pressure-overload hypertrophy in infant myocardium. J. Thorac. Cardiovasc. Surg., June 1, 2009; 137(6): 1356 - 1362.e3. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Jaffre, P. Bonnin, J. Callebert, H. Debbabi, V. Setola, S. Doly, L. Monassier, B. Mettauer, B. C. Blaxall, J.-M. Launay, et al. Serotonin and Angiotensin Receptors in Cardiac Fibroblasts Coregulate Adrenergic-Dependent Cardiac Hypertrophy Circ. Res., January 2, 2009; 104(1): 113 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Athirakul, J. A. Bradbury, J. P. Graves, L. M. DeGraff, J. Ma, Y. Zhao, J. F. Couse, R. Quigley, D. R. Harder, X. Zhao, et al. Increased blood pressure in mice lacking cytochrome P450 2J5 FASEB J, December 1, 2008; 22(12): 4096 - 4108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Gallo, M. V.G. Latronico, P. Gallo, S. Grimaldi, F. Borgia, M. Todaro, P. Jones, P. Gallinari, R. De Francesco, G. Ciliberto, et al. Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure Cardiovasc Res, December 1, 2008; 80(3): 416 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Kushwaha, E. Raichlin, Y. Sheinin, W. K. Kremers, K. Chandrasekaran, G. J. Brunn, and J. L. Platt Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant recipients Eur. Heart J., November 2, 2008; 29(22): 2742 - 2750. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Hedhli, P. Lizano, C. Hong, L. F. Fritzky, S. K. Dhar, H. Liu, Y. Tian, S. Gao, K. Madura, S. F. Vatner, et al. Proteasome inhibition decreases cardiac remodeling after initiation of pressure overload Am J Physiol Heart Circ Physiol, October 1, 2008; 295(4): H1385 - H1393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bourajjaj, A.-S. Armand, P. A. da Costa Martins, B. Weijts, R. van der Nagel, S. Heeneman, X. H. Wehrens, and L. J. De Windt NFATc2 Is a Necessary Mediator of Calcineurin-dependent Cardiac Hypertrophy and Heart Failure J. Biol. Chem., August 8, 2008; 283(32): 22295 - 22303. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Jacobshagen, M. Gruber, N. Teucher, A. G. Schmidt, B. W. Unsold, K. Toischer, P. Nguyen Van, L. S. Maier, H. Kogler, and G. Hasenfuss Celecoxib modulates hypertrophic signalling and prevents load-induced cardiac dysfunction Eur J Heart Fail, April 1, 2008; 10(4): 334 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Hill and E. N. Olson Cardiac Plasticity N. Engl. J. Med., March 27, 2008; 358(13): 1370 - 1380. [Full Text] [PDF]
|
|
|
|
|
|
B. R. DeGeorge Jr, E. Gao, M. Boucher, L. E. Vinge, J. S. Martini, P. W. Raake, J. K. Chuprun, D. M. Harris, G. W. Kim, S. Soltys, et al. Targeted Inhibition of Cardiomyocyte Gi Signaling Enhances Susceptibility to Apoptotic Cell Death in Response to Ischemic Stress Circulation, March 18, 2008; 117(11): 1378 - 1387. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Woodcock, X.-J. Du, M. E. Reichelt, and R. M. Graham Cardiac {alpha}1-adrenergic drive in pathological remodelling Cardiovasc Res, February 1, 2008; 77(3): 452 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Diwan, J. Wansapura, F. M. Syed, S. J. Matkovich, J. N. Lorenz, and G. W. Dorn II Nix-Mediated Apoptosis Links Myocardial Fibrosis, Cardiac Remodeling, and Hypertrophy Decompensation Circulation, January 22, 2008; 117(3): 396 - 404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pokreisz, G. Marsboom, and S. Janssens Pressure overload-induced right ventricular dysfunction and remodelling in experimental pulmonary hypertension: the right heart revisited Eur. Heart J. Suppl., December 1, 2007; 9(suppl_H): H75 - H84. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Liggett, R. J. Kelly, R. R. Parekh, S. J. Matkovich, B. J. Benner, H. S. Hahn, F. M. Syed, A. S. Galvez, K. L. Case, N. McGuire, et al. A functional polymorphism of the G{alpha}q (GNAQ) gene is associated with accelerated mortality in African-American heart failure Hum. Mol. Genet., November 15, 2007; 16(22): 2740 - 2750. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Zhai, S. Gao, E. Holle, X. Yu, A. Yatani, T. Wagner, and J. Sadoshima Glycogen Synthase Kinase-3{alpha} Reduces Cardiac Growth and Pressure Overload-induced Cardiac Hypertrophy by Inhibition of Extracellular Signal-regulated Kinases J. Biol. Chem., November 9, 2007; 282(45): 33181 - 33191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Harris, H. I. Cohn, S. Pesant, R.-H. Zhou, and A. D. Eckhart Vascular smooth muscle Gq signaling is involved in high blood pressure in both induced renal and genetic vascular smooth muscle-derived models of hypertension Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H3072 - H3079. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.-G. Kerfant, D. Zhao, I. Lorenzen-Schmidt, L. S. Wilson, S. Cai, S. R. W. Chen, D. H. Maurice, and P. H. Backx PI3K{gamma} Is Required for PDE4, not PDE3, Activity in Subcellular Microdomains Containing the Sarcoplasmic Reticular Calcium ATPase in Cardiomyocytes Circ. Res., August 17, 2007; 101(4): 400 - 408. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Cingolani, G. A. Ramirez Correa, E. Kizana, M. Murata, H. C. Cho, and E. Marban Gene Therapy to Inhibit the Calcium Channel {beta} Subunit: Physiological Consequences and Pathophysiological Effects in Models of Cardiac Hypertrophy Circ. Res., July 20, 2007; 101(2): 166 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Diwan and G. W. Dorn II Decompensation of Cardiac Hypertrophy: Cellular Mechanisms and Novel Therapeutic Targets Physiology, February 1, 2007; 22(1): 56 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Sharma, I. C. Okere, M. K. Duda, D. J. Chess, K. M. O'Shea, and W. C. Stanley Potential impact of carbohydrate and fat intake on pathological left ventricular hypertrophy Cardiovasc Res, January 15, 2007; 73(2): 257 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. C. Okere, M. E. Young, T. A. McElfresh, D. J. Chess, V. G. Sharov, H. N. Sabbah, B. D. Hoit, P. Ernsberger, M. P. Chandler, and W. C. Stanley Low Carbohydrate/High-Fat Diet Attenuates Cardiac Hypertrophy, Remodeling, and Altered Gene Expression in Hypertension Hypertension, December 1, 2006; 48(6): 1116 - 1123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Rajagopal, E. J. Whalen, J. D. Violin, J. A. Stiber, P. B. Rosenberg, R. T. Premont, T. M. Coffman, H. A. Rockman, and R. J. Lefkowitz beta-Arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes PNAS, October 31, 2006; 103(44): 16284 - 16289. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Curcio, T. Noma, S. V. Naga Prasad, M. J. Wolf, A. Lemaire, C. Perrino, L. Mao, and H. A. Rockman Competitive displacement of phosphoinositide 3-kinase from beta-adrenergic receptor kinase-1 improves postinfarction adverse myocardial remodeling Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1754 - H1760. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Most, H. Seifert, E. Gao, H. Funakoshi, M. Volkers, J. Heierhorst, A. Remppis, S. T. Pleger, B. R. DeGeorge Jr, A. D. Eckhart, et al. Cardiac S100A1 Protein Levels Determine Contractile Performance and Propensity Toward Heart Failure After Myocardial Infarction Circulation, September 19, 2006; 114(12): 1258 - 1268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Zhai, J. Galeotti, J. Liu, E. Holle, X. Yu, T. Wagner, and J. Sadoshima An Angiotensin II Type 1 Receptor Mutant Lacking Epidermal Growth Factor Receptor Transactivation Does Not Induce Angiotensin II-Mediated Cardiac Hypertrophy Circ. Res., September 1, 2006; 99(5): 528 - 536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Seubert, C. J. Sinal, J. Graves, L. M. DeGraff, J. A. Bradbury, C. R. Lee, K. Goralski, M. A. Carey, A. Luria, J. W. Newman, et al. Role of Soluble Epoxide Hydrolase in Postischemic Recovery of Heart Contractile Function Circ. Res., August 18, 2006; 99(4): 442 - 450. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Dorn II Containing Hypertrophy With a PICOT Fence Circ. Res., August 4, 2006; 99(3): 228 - 230. [Full Text] [PDF]
|
|
|
|
|
|
N. J. Smith and L. M. Luttrell Signal Switching, Crosstalk, and Arrestin Scaffolds: Novel G Protein-Coupled Receptor Signaling in Cardiovascular Disease Hypertension, August 1, 2006; 48(2): 173 - 179. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Swynghedauw Phenotypic plasticity of adult myocardium: molecular mechanisms J. Exp. Biol., June 15, 2006; 209(12): 2320 - 2327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Matsui, T. Nagoshi, E.-G. Hong, I. Luptak, K. Hartil, L. Li, N. Gorovits, M. J. Charron, J. K. Kim, R. Tian, et al. Effects of chronic Akt activation on glucose uptake in the heart Am J Physiol Endocrinol Metab, May 1, 2006; 290(5): E789 - E797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Perrino and H. A. Rockman GATA4 and the Two Sides of Gene Expression Reprogramming Circ. Res., March 31, 2006; 98(6): 715 - 716. [Full Text] [PDF]
|
|
|
|
|
|
T. Oka, M. Maillet, A. J. Watt, R. J. Schwartz, B. J. Aronow, S. A. Duncan, and J. D. Molkentin Cardiac-Specific Deletion of Gata4 Reveals Its Requirement for Hypertrophy, Compensation, and Myocyte Viability Circ. Res., March 31, 2006; 98(6): 837 - 845. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Chambers The left ventricle in aortic stenosis: evidence for the use of ACE inhibitors. Heart, March 1, 2006; 92(3): 420 - 423. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. J. Kang Cardiac Hypertrophy: A Risk Factor for QT-Prolongation and Cardiac Sudden Death Toxicol Pathol, January 1, 2006; 34(1): 58 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Munch, K. Rosport, A. Bultmann, C. Baumgartner, Z. Li, L. Laacke, and M. Ungerer Cardiac Overexpression of the Norepinephrine Transporter Uptake-1 Results in Marked Improvement of Heart Failure Circ. Res., October 28, 2005; 97(9): 928 - 936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Wettschureck and S. Offermanns Mammalian G Proteins and Their Cell Type Specific Functions Physiol Rev, October 1, 2005; 85(4): 1159 - 1204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kupari, H. Turto, and J. Lommi Left ventricular hypertrophy in aortic valve stenosis: preventive or promotive of systolic dysfunction and heart failure? Eur. Heart J., September 1, 2005; 26(17): 1790 - 1796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. P.J. Buermans and W. J. Paulus Iconoclasts topple adaptive myocardial hypertrophy in aortic stenosis Eur. Heart J., September 1, 2005; 26(17): 1697 - 1699. [Full Text] [PDF]
|
|
|
|
|
|
C. F. Deschepper The Many Possible Benefits of Natriuretic Peptides After Myocardial Infarction Hypertension, August 1, 2005; 46(2): 271 - 272. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Perrino, S. V. Naga Prasad, M. Patel, M. J. Wolf, and H. A. Rockman Targeted Inhibition of {beta}-Adrenergic Receptor Kinase-1-Associated Phosphoinositide-3 Kinase Activity Preserves {beta}-Adrenergic Receptor Signaling and Prolongs Survival in Heart Failure Induced by Calsequestrin Overexpression J. Am. Coll. Cardiol., June 7, 2005; 45(11): 1862 - 1870. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.-G. Kerfant, D. Gidrewicz, H. Sun, G. Y. Oudit, J. M. Penninger, and P. H. Backx Cardiac Sarcoplasmic Reticulum Calcium Release and Load Are Enhanced by Subcellular cAMP Elevations in PI3K{gamma}-Deficient Mice Circ. Res., May 27, 2005; 96(10): 1079 - 1086. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. De Acetis, A. Notte, F. Accornero, G. Selvetella, M. Brancaccio, C. Vecchione, M. Sbroggio, F. Collino, B. Pacchioni, G. Lanfranchi, et al. Cardiac Overexpression of Melusin Protects From Dilated Cardiomyopathy Due to Long-Standing Pressure Overload Circ. Res., May 27, 2005; 96(10): 1087 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Perrino, S. V. Naga Prasad, J. N. Schroder, J. A. Hata, C. Milano, and H. A. Rockman Restoration of {beta}-Adrenergic Receptor Signaling and Contractile Function in Heart Failure by Disruption of the {beta}ARK1/Phosphoinositide 3-Kinase Complex Circulation, May 24, 2005; 111(20): 2579 - 2587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kozakova, A. G. Fraser, S. Buralli, A. Magagna, A. Salvetti, E. Ferrannini, and C. Palombo Reduced Left Ventricular Functional Reserve in Hypertensive Patients With Preserved Function at Rest Hypertension, April 1, 2005; 45(4): 619 - 624. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Booz Putting the Brakes on Cardiac Hypertrophy: Exploiting the NO-cGMP Counter-Regulatory System Hypertension, March 1, 2005; 45(3): 341 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Tachibana, S. V. Naga Prasad, R. J. Lefkowitz, W. J. Koch, and H. A. Rockman Level of {beta}-Adrenergic Receptor Kinase 1 Inhibition Determines Degree of Cardiac Dysfunction After Chronic Pressure Overload-Induced Heart Failure Circulation, February 8, 2005; 111(5): 591 - 597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Arya, V. Kedar, J. R. Hwang, H. McDonough, H.-H. Li, J. Taylor, and C. Patterson Muscle ring finger protein-1 inhibits PKC{epsilon} activation and prevents cardiomyocyte hypertrophy J. Cell Biol., December 20, 2004; 167(6): 1147 - 1159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Holmes Candidate mechanical stimuli for hypertrophy during volume overload J Appl Physiol, October 1, 2004; 97(4): 1453 - 1460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Seubert, B. Yang, J. A. Bradbury, J. Graves, L. M. Degraff, S. Gabel, R. Gooch, J. Foley, J. Newman, L. Mao, et al. Enhanced Postischemic Functional Recovery in CYP2J2 Transgenic Hearts Involves Mitochondrial ATP-Sensitive K+ Channels and p42/p44 MAPK Pathway Circ. Res., September 3, 2004; 95(5): 506 - 514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Selvetella, E. Hirsch, A. Notte, G. Tarone, and G. Lembo Adaptive and maladaptive hypertrophic pathways: points of convergence and divergence Cardiovasc Res, August 15, 2004; 63(3): 373 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Barki-Harrington, C. Perrino, and H. A Rockman Network integration of the adrenergic system in cardiac hypertrophy Cardiovasc Res, August 15, 2004; 63(3): 391 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Fiedler and K. C Wollert Interference of antihypertrophic molecules and signaling pathways with the Ca2+-calcineurin-NFAT cascade in cardiac myocytes Cardiovasc Res, August 15, 2004; 63(3): 450 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. P.M van Empel and L. J De Windt Myocyte hypertrophy and apoptosis: a balancing act Cardiovasc Res, August 15, 2004; 63(3): 487 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Frey, H. A. Katus, E. N. Olson, and J. A. Hill Hypertrophy of the Heart: A New Therapeutic Target? Circulation, April 6, 2004; 109(13): 1580 - 1589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. de Simone Concentric or Eccentric Hypertrophy: How Clinically Relevant Is the Difference? Hypertension, April 1, 2004; 43(4): 714 - 715. [Full Text] [PDF]
|
|
|
|
|
|
E. van Rooij, P. A. Doevendans, H. J.G.M. Crijns, S. Heeneman, D. J. Lips, M. van Bilsen, R. S. Williams, E. N. Olson, R. Bassel-Duby, B. A. Rothermel, et al. MCIP1 Overexpression Suppresses Left Ventricular Remodeling and Sustains Cardiac Function After Myocardial Infarction Circ. Res., February 20, 2004; 94 (3): e18 - e26. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Dorn II and J. D. Molkentin Manipulating Cardiac Contractility in Heart Failure: Data From Mice and Men Circulation, January 20, 2004; 109(2): 150 - 158. [Full Text] [PDF]
|
|
|
|
 |
|
 J.R. Keys and W.J. Koch The Adrenergic Pathway and Heart Failure Recent Prog. Horm. Res., January 1, 2004; 59(1): 13 - 30. [Abstract] [Full Text]
|
|
|
|
|
|
P. Le Corvoisier, H.-Y. Park, K. M. Carlson, D. A. Marchuk, and H. A. Rockman Multiple quantitative trait loci modify the heart failure phenotype in murine cardiomyopathy Hum. Mol. Genet., December 1, 2003; 12(23): 3097 - 3107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Liao, S. Takashima, Y. Asano, M. Asakura, A. Ogai, Y. Shintani, T. Minamino, H. Asanuma, S. Sanada, J. Kim, et al. Activation of Adenosine A1 Receptor Attenuates Cardiac Hypertrophy and Prevents Heart Failure in Murine Left Ventricular Pressure-Overload Model Circ. Res., October 17, 2003; 93(8): 759 - 766. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. McMullen, T. Shioi, L. Zhang, O. Tarnavski, M. C. Sherwood, P. M. Kang, and S. Izumo Phosphoinositide 3-kinase(p110{alpha}) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy PNAS, October 14, 2003; 100(21): 12355 - 12360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Barki-Harrington, L. M. Luttrell, and H. A. Rockman Dual Inhibition of {beta}-Adrenergic and Angiotensin II Receptors by a Single Antagonist: A Functional Role for Receptor-Receptor Interaction In Vivo Circulation, September 30, 2003; 108(13): 1611 - 1618. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Chen, S. Park, Y. Li, E. Missov, M. Hou, X. Han, J. L. Hall, L. W. Miller, and R. J. Bache Alterations of gene expression in failing myocardium following left ventricular assist device support Physiol Genomics, August 15, 2003; 14(3): 251 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Antos, T. A. McKinsey, M. Dreitz, L. M. Hollingsworth, C.-L. Zhang, K. Schreiber, H. Rindt, R. J. Gorczynski, and E. N. Olson Dose-dependent Blockade to Cardiomyocyte Hypertrophy by Histone Deacetylase Inhibitors J. Biol. Chem., August 1, 2003; 278(31): 28930 - 28937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Schoenmakers, C. Ramakers, J. M. van Opstal, J. D.M. Leunissen, C. Londono, and M. A. Vos Asynchronous development of electrical remodeling and cardiac hypertrophy in the complete AV block dog Cardiovasc Res, August 1, 2003; 59(2): 351 - 359. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Dorn II, J. Robbins, and P. H. Sugden Phenotyping Hypertrophy: Eschew Obfuscation Circ. Res., June 13, 2003; 92(11): 1171 - 1175. [Full Text] [PDF]
|
|
|
|
|
|
D. J. Lips, L. J. deWindt, D. J.W. van Kraaij, and P. A. Doevendans Molecular determinants of myocardial hypertrophy and failure: alternative pathways for beneficial and maladaptive hypertrophy Eur. Heart J., May 2, 2003; 24(10): 883 - 896. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. S. Scopacasa, V. P. A. Teixeira, and K. G. Franchini Colchicine attenuates left ventricular hypertrophy but preserves cardiac function of aortic-constricted rats J Appl Physiol, April 1, 2003; 94(4): 1627 - 1633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Morisco, J. Sadoshima, B. Trimarco, R. Arora, D. E. Vatner, and S. F. Vatner Is treating cardiac hypertrophy salutary or detrimental: the two faces of Janus Am J Physiol Heart Circ Physiol, April 1, 2003; 284 (4): H1043 - H1047. [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Colomer, L. Mao, H. A. Rockman, and A. R. Means Pressure Overload Selectively Up-Regulates Ca2+/Calmodulin-Dependent Protein Kinase II in Vivo Mol. Endocrinol., February 1, 2003; 17(2): 183 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Sjaastad, J A. Wasserstrom, and O. M Sejersted Heart failure - a challenge to our current concepts of excitation-contraction coupling J. Physiol., January 1, 2003; 546(1): 33 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nemoto, G. DeFreitas, D. L. Mann, and B. A. Carabello Effects of changes in left ventricular contractility on indexes of contractility in mice Am J Physiol Heart Circ Physiol, December 1, 2002; 283(6): H2504 - H2510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Sussman, A. McCulloch, and T. K. Borg Dance Band on the Titanic: Biomechanical Signaling in Cardiac Hypertrophy Circ. Res., November 15, 2002; 91(10): 888 - 898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Keys, E. A. Greene, W. J. Koch, and A. D. Eckhart Gq-Coupled Receptor Agonists Mediate Cardiac Hypertrophy Via the Vasculature Hypertension, November 1, 2002; 40(5): 660 - 666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Nishio, S. Sasayama, and A. Matsumori Left ventricular pressure-volume relationship in a murine model of congestive heart failure due to acute viral myocarditis J. Am. Coll. Cardiol., October 16, 2002; 40(8): 1506 - 1514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Indolfi, E. Di Lorenzo, C. Perrino, A. M. Stingone, A. Curcio, D. Torella, A. Cittadini, L. Cardone, C. Coppola, L. Cavuto, et al. Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor Simvastatin Prevents Cardiac Hypertrophy Induced by Pressure Overload and Inhibits p21ras Activation Circulation, October 15, 2002; 106(16): 2118 - 2124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Fatkin and R. M. Graham Molecular Mechanisms of Inherited Cardiomyopathies Physiol Rev, October 1, 2002; 82(4): 945 - 980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kim, A. D. Eckhart, S. Eguchi, and W. J. Koch beta -Adrenergic Receptor-mediated DNA Synthesis in Cardiac Fibroblasts Is Dependent on Transactivation of the Epidermal Growth Factor Receptor and Subsequent Activation of Extracellular Signal-regulated Kinases J. Biol. Chem., August 23, 2002; 277(35): 32116 - 32123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J Wilkins and J. D Molkentin Calcineurin and cardiac hypertrophy: Where have we been? Where are we going? J. Physiol., May 15, 2002; 541(1): 1 - 8. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Hill, B. Rothermel, K.-D. Yoo, B. Cabuay, E. Demetroulis, R. M. Weiss, W. Kutschke, R. Bassel-Duby, and R. S. Williams Targeted Inhibition of Calcineurin in Pressure-overload Cardiac Hypertrophy. PRESERVATION OF SYSTOLIC FUNCTION J. Biol. Chem., March 15, 2002; 277(12): 10251 - 10255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.V. NAGA PRASAD, J. NIENABER, and H.A. ROCKMAN G-Protein-coupled Receptor Function in Heart Failure Cold Spring Harb Symp Quant Biol, January 1, 2002; 67(0): 439 - 444. [Abstract] [PDF]
|
|
|
|
|
|
M. Sano and M. D. Schneider Still Stressed Out but Doing Fine: Normalization of Wall Stress Is Superfluous to Maintaining Cardiac Function in Chronic Pressure Overload Circulation, January 1, 2002; 105(1): 8 - 10. [Full Text] [PDF]
|
|
|
|
|
|
M. Suzuki, K. M. Carlson, D. A. Marchuk, and H. A. Rockman Genetic Modifier Loci Affecting Survival and Cardiac Function in Murine Dilated Cardiomyopathy Circulation, April 16, 2002; 105(15): 1824 - 1829. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||